Your browser doesn't support javascript.
Towards effective COVID­19 vaccines: Updates, perspectives and challenges (Review).
Calina, Daniela; Docea, Anca Oana; Petrakis, Demetrios; Egorov, Alex M; Ishmukhametov, Aydar A; Gabibov, Alexsandr G; Shtilman, Michael I; Kostoff, Ronald; Carvalho, Félix; Vinceti, Marco; Spandidos, Demetrios A; Tsatsakis, Aristidis.
  • Calina D; Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Docea AO; Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Petrakis D; Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.
  • Egorov AM; FSBSI 'Chumakov Federal Scientific Center for Research and Development of Immune­ and Biological Products of Russian Academy of Sciences', 108819 Moscow, Russia.
  • Ishmukhametov AA; FSBSI 'Chumakov Federal Scientific Center for Research and Development of Immune­ and Biological Products of Russian Academy of Sciences', 108819 Moscow, Russia.
  • Gabibov AG; Russian Academy of Sciences, 119991 Moscow, Russia.
  • Shtilman MI; D.I. Mendeleyev University of Chemical Technology, 125047 Moscow, Russia.
  • Kostoff R; School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, USA.
  • Carvalho F; UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050­313 Porto, Portugal.
  • Vinceti M; Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, I-41125 Modena, Italy.
  • Spandidos DA; Laboratory of Clinical Virology, Medical School, University of Crete, 71409 Heraklion, Greece.
  • Tsatsakis A; Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.
Int J Mol Med ; 46(1): 3-16, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-2225841
ABSTRACT
In the current context of the pandemic triggered by SARS-COV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS­COV­2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a COVID­19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int J Mol Med Journal subject: Molecular Biology / Genetics, Medical Year: 2020 Document Type: Article Affiliation country: Ijmm.2020.4596

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int J Mol Med Journal subject: Molecular Biology / Genetics, Medical Year: 2020 Document Type: Article Affiliation country: Ijmm.2020.4596